H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $38 from $30 and keeps a Buy rating on the shares after the company ...

H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...

On Friday, Energy Fuels Inc (UUUU) stock saw a modest uptick, ending the day at $7.29 which represents a slight increase of $0.49 or 7.21% from the prior close of $6.8. The stock opened at $7.1 and ...

H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares ...

Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company ...

H.C. Wainwright has recently raised Syros Pharmaceuticals Inc (SYRS) stock to Buy rating, as announced on November 4, 2020, according to Finviz. Earlier, on September 22, 2020, Alliance Global ...

The Company clarified that they are not obligated to sell any Shares under this agreement. H.C. Wainwright & Co., LLC will act to sell the Shares based on electroCore’s instructions and within the ...

Thanks to the Securities and Exchange Commission, you don't have to. Artificial intelligence (AI) has been the stock market's ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...

H.C. Wainwright analyst Arthur He downgraded Poseida Therapeutics (PSTX) to Neutral from Buy with a price target of $9, down from $20, after Roche (RHHBY) agreed to acquire the company for $1.5B ...

H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...

To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...